Cell News and Research

RSS

New findings may help develop potential therapies for lupus, rheumatoid arthritis and cancer

Medical Research Council (MRC) scientists at the University of Leicester have made a new advance in understanding how the body fights certain types of cancer and other disease such as Lupus and rheumatoid arthritis.

15 Mar 2010

Keystone Symposia receives NIH grant for diversity initiatives

Keystone Symposia on Molecular and Cellular Biology is pleased to announce receipt of a $1.37 million, five-year MARC (Minority Access to Research Careers) Ancillary Training Activities grant from the National Institute of General Medical Sciences of the National Institutes of Health (NIH).

15 Mar 2010

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Ligand Pharmaceuticals Incorporated today announced that GlaxoSmithKline was granted marketing authorization from the European Commission for Revolade® (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

15 Mar 2010

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

Cancer cells in rapidly growing brain tumors must adjust to periods of low energy or die. When energy levels are high, tumor cells grow and proliferate. When levels are low, the cells grow less and migrate more.

15 Mar 2010

UVA, Merck collaborate to discover novel drugs for women's reproductive health

The University of Virginia in Charlottesville today announced that it has entered into a research collaboration with Merck (known as MSD outside the United States and Canada) to discover novel drugs for women's reproductive health.

12 Mar 2010

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.

12 Mar 2010

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

BeaconEquity.com announces an investment report featuring biotechnology company BioSante Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

12 Mar 2010

Genetix Pharmaceuticals announces completion of $35M Series B financing

Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.

12 Mar 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for full year and fourth quarter, ended December 31, 2009. These results are included in the Company’s Annual Report on Form 10-K which has been filed with the SEC.

12 Mar 2010

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.

12 Mar 2010

Cytori Therapeutics reports total revenues of $14.7M for 2009

Cytori Therapeutics is reporting its financial results for the year ended December 31, 2009.

From Evident Corporation - Life Sciences 12 Mar 2010

New SpermCheck Fertility home test kit for sperm level measurement

Infertility affects between 10 and 15 percent of couples worldwide. Surprisingly, problems with male fertility account for approximately 50 percent of infertility cases.

12 Mar 2010

New method to better study prostate cancer

Van Andel Research Institute researchers have developed a new method to better study the cells that line and protect the prostate in relation to the development of cancer. Using the model, they found that normal cells and cancer cells depend on different factors to survive, which could aid in discovering how to target cancer cells without affecting normal cells when developing treatments.

12 Mar 2010

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.

12 Mar 2010

Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC

Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).

12 Mar 2010

VisEn Medical introduces VivoTag 680 XL fluorescent dye for labeling biomolecules

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new VivoTag® 680 XL fluorescent dye for labeling biomolecules in a broad range of in vitro and in vivo imaging applications.

12 Mar 2010

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063.

12 Mar 2010

Cell News and Research

New findings may help develop potential therapies for lupus, rheumatoid arthritis and cancer

Keystone Symposia receives NIH grant for diversity initiatives

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

UVA, Merck collaborate to discover novel drugs for women's reproductive health

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

Genetix Pharmaceuticals announces completion of $35M Series B financing

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

Cytori Therapeutics reports total revenues of $14.7M for 2009

New SpermCheck Fertility home test kit for sperm level measurement

New method to better study prostate cancer

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC

VisEn Medical introduces VivoTag 680 XL fluorescent dye for labeling biomolecules

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

Discovery of novel cellular mechanism may help develop new treatments for cancer

Novel mutation in gene encoding ankyrin-B increases risk of type 2 diabetes

TGen, Virginia G. Piper Cancer Center and Side-Out Foundation team up for breast cancer study

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo